What’s the difference between subcutaneous and intramuscular injection for peptides?

Subcutaneous injection deposits a medicine in the fatty tissue beneath the skin; intramuscular injection places it in muscle. Blood flow, local tissue conditions, molecular size, and formulation can change how quickly the medicine reaches circulation and the shape of its concentration curve. Intramuscular administration is not universally more complete or more effective. Some glucagon products support both routes, with measured differences in absorption timing.[1]

Approved semaglutide and tirzepatide injections are formulated and studied for subcutaneous use. Their evidence does not establish that injecting into muscle improves fat loss or avoids side effects. The clinically useful exposure depends on more than the speed of absorption. Some medicines use route-specific formulations, so a protocol specifying a route may reflect the actual clinical trials and product design rather than a general preference.[2][3]

Both routes can cause local pain or tissue reactions, and an incorrectly chosen route introduces avoidable uncertainty. Systemic side effects depend on the medicine and exposure, not only on the injection site. For experimental peptides, robust human comparisons are often absent, so claims that one route is superior need direct evidence. Use the route specified for the prescribed formulation rather than treating the same volume as automatically interchangeable.[1][2][3]